


Fig. 1






Fig. 3




Fig. 4




Fig. 5





Fig. 6

sample	n	CD19+/IgG+	IgG/IgD+	CD19+/IgM+	IgM+/IgD+	CD19+/CD38+	CD19/CD40	CD19/CD95
TIL	6	95	40	30	66	30	95	11
tumor-draining lymph node	5	53	20	25	73	37	86	14
PBMC- breast cancer pt	5	41	34	47	90	46	65	45
PBMC - healthy donor	4	23	1	70	90	1	25	22

TILB

marker	specificity
BCL2	antiapoptotic
CD10	pre-B
CD20	B
CD23	activation
CD27	memory
CD38	plasma cell
CD5	T, autoimmune B
HLADR	B / APC
Ki-67/CD20	B cell, proliferation

Tumor-infiltrating lymphocytes



Normal PBMC




Fig. 7




Fig. 8